Looking Beyond Everyday Knee Pain
Knee osteoarthritis can turn simple activities like walking, climbing stairs, or getting out of a chair into uncomfortable tasks. While cartilage changes are part of the condition, inflammation inside the joint can also play an important role in pain and stiffness.
A recent randomized clinical trial explored whether umbilical cord-derived mesenchymal stem cells, or UC-MSCs, could help people with knee osteoarthritis. Researchers were especially interested in patients who also had synovitis, which is inflammation of the tissue lining the knee joint.
Putting UC-MSCs to the Test
The study screened 69 people and ultimately randomized 55 participants into three groups. Patients received either a UC-MSC injection, a commonly used hyaluronic acid injection, or a placebo injection directly into the affected knee.
The UC-MSC treatment contained 20 million cells and was given as a single injection. Researchers followed participants for about six months.
During follow-up, they looked at:
- Knee pain and stiffness
- Physical function
- Quality of life
- MRI changes inside the joint
- Treatment safety
Using three different groups gave researchers a useful way to compare UC-MSC treatment with both placebo and a commonly used knee injection.
Where the Most Interesting Results Appeared
When researchers looked at the entire study population, the UC-MSC group did not perform significantly better across every measurement. But a more interesting pattern appeared when they focused on patients who had osteoarthritis along with synovitis.
After 24 weeks, MRI scans showed a significant improvement in joint inflammation in the UC-MSC group. The placebo and hyaluronic acid groups did not show the same significant change.
Patients with synovitis who received UC-MSCs also improved on the WOMAC score, a common measurement of knee pain, stiffness, and difficulty performing everyday activities.
Pain Levels Seemed to Matter
Researchers then took a closer look at patients who had joint inflammation along with moderate to severe knee pain. This group showed some of the most encouraging results.
Compared with the other treatment groups, UC-MSC patients showed improvements in areas including:
- Knee pain
- Joint symptoms
- Everyday physical function
- Overall quality of life
This suggests that the condition of the knee before treatment may matter. UC-MSC therapy may have greater potential in people whose osteoarthritis includes a stronger inflammatory component.
What Did the MRI Scans Show?
The MRI findings added another interesting piece to the study. Researchers saw improvement in synovitis and fluid buildup inside the joint in the UC-MSC group. However, they did not find significant differences in cartilage damage or bone marrow changes between the three groups after six months.
That distinction is important. The study showed encouraging changes in inflammation and patient symptoms, but it did not demonstrate clear cartilage regeneration during the study period.
How Did the Treatment Perform for Safety?
UC-MSC treatment was generally well tolerated. Researchers reported no serious treatment-related adverse events, deaths, joint infections, tumors, or permanent disabilities during the study.
Some patients experienced temporary discomfort after treatment. Reported reactions included:
- Short-term pain around the injection site
- Mild swelling or discomfort
- One brief mild fever
These effects were temporary and resolved quickly. Overall, the safety profile of the UC-MSC treatment was similar to the placebo and hyaluronic acid groups.
A More Targeted Look at Regenerative Joint Care
One of the most interesting lessons from this trial is that knee osteoarthritis may not behave exactly the same in every patient.
The strongest results appeared in people who had both osteoarthritis and inflammation inside the knee, particularly those with moderate to severe pain. In these patients, UC-MSC therapy was associated with improvements in pain, function, quality of life, and MRI signs of synovitis.
The study was relatively small and followed patients for only six months, so larger trials and longer follow-up will still be needed. Even so, the findings point toward an important direction in regenerative medicine: understanding not only whether a treatment may help, but which patients may be most likely to benefit from it.
Source
Tong W, Shi Y, Wu D, et al. Intra-articular injection of umbilical cord-derived mesenchymal stem cells is safe and effective for moderate to severe knee osteoarthritis with synovitis: a double-blinded and randomized controlled trial. BMC Musculoskeletal Disorders. 2026;27:84. doi: 10.1186/s12891-025-09440-y. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12859901/
Related Treatment Pages